Abivax cancer risk framed as mispriced overhang
The speakers argued that market concerns around a cancer signal in Abivax's ulcerative colitis trial are unfounded, creating a severe valuation disconnect ahead of upcoming safety data and potential M&A.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.